Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | CCNC | P24863 | 14/20 | 0.54 |
| ▸ | CDK8 | P49336 | 14/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24166521 | 0.85 | HPGD (0.63) | EPHX2HPGDNAMPT | |
| SCHEMBL8358137 | 0.83 | SIGMAR1 (0.81) | SIGMAR1EPHX2HPGD | |
| SCHEMBL1019077 | 0.82 | SIGMAR1 (0.69) | SIGMAR1EPHX2FLT3CCNCCDK8 | |
| SCHEMBL30798838 | 0.82 | SIGMAR1 (0.68) | SIGMAR1HPGD | |
| SCHEMBL1429288 | 0.81 | EPHX2 (0.68) | EPHX2FLT3HPGDNAMPTPOLB | |
| SCHEMBL30410369 | 0.81 | EPHX2 (0.68) | EPHX2HPGDNAMPTPOLB | |
| SCHEMBL8357615 | 0.79 | SIGMAR1 (0.64) | SIGMAR1HPGD | |
| SCHEMBL1409459 | 0.78 | SIGMAR1 (0.68) | SIGMAR1CCNCCDK8HPGD | |
| Hydrochloric Acid SCHEMBL10680333 | 0.78 | EPHX2 (0.49) | SIGMAR1EPHX2FLT3CCNCCDK8 | |
| SCHEMBL14368348 | 0.78 | SIGMAR1 (0.58) | SIGMAR1EPHX2FLT3CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | claimed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | claimed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | claimed |
| EP-2318368-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. Organon (NL) | 2011-05-11 | — | — | EP | claimed |
| WO-2010025179-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2010-03-04 | — | — | WO | claimed |
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| US-8759352-B2 | 1-(4-ureidobenzoyl)piperazine derivatives | MERCK SHARP & DOHME B.V. (NL) | 2014-06-24 | — | — | US | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| EP-2318368-B1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | MERCK SHARP & DOHME (NL) | 2013-10-16 | — | — | EP | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2012-01-19 | — | — | US | disclosed |
| CN-102131781-A | 1-(4-ureidobenzoyl)piperazine derivatives | ORGANON NV | 2011-07-20 | — | — | CN | disclosed |
| CN-102131781-A | 1-(4-ureidobenzoyl)piperazine derivatives | ORGANON NV | 2011-07-20 | — | — | CN | disclosed |
| EP-2318368-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. Organon (NL) | 2011-05-11 | — | — | EP | disclosed |
| EP-2318368-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. Organon (NL) | 2011-05-11 | — | — | EP | disclosed |
| EP-2318368-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. Organon (NL) | 2011-05-11 | — | — | EP | disclosed |
| WO-2010025179-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025179-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010025179-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | N.V. ORGANON (NL) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015958-A1 | 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES | NPC1, ABCB11, NPC1L1 | SIGMAR1 249/4885EPHX2 1501/4885FLT3 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.